Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.05 USD | -1.43% | +1.21% | -27.04% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.04% | 1.55B | |
-19.84% | 10.81B | |
+52.09% | 3.36B | |
-33.16% | 2.22B | |
-14.15% | 2.16B | |
+21.45% | 1.04B | |
-2.62% | 746M | |
-31.50% | 425M | |
-43.78% | 405M | |
+29.03% | 378M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Goldman Sachs Cuts Price Target on Veracyte to $32 From $35, Noting Decline in Peer Multiples; Buy Rating Maintained